U.K. Biotech Renovo's Future On The Line As Phase III Lead Crashes
This article was originally published in The Pink Sheet Daily
Executive Summary
The Phase III failure of Renovo's scar reduction treatment threatens the company's future and is the latest in a string of bad news for U.K. biotech.